Suppr超能文献

用于膀胱出口梗阻的热膨胀性前列腺支架:一项8年的研究。

Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study.

作者信息

Perry M J A, Roodhouse A J, Gidlow A B, Spicer T G, Ellis B W

机构信息

Department of Urology, Ashford and St Peter's Hospital, Middlesex, UK.

出版信息

BJU Int. 2002 Aug;90(3):216-23. doi: 10.1046/j.1464-410x.2002.02888.x.

Abstract

OBJECTIVE

To assess the use of a thermo-expandable intraprostatic stent (Memokath(R), Engineers and Doctors A/S, Copenhagen, Denmark) for bladder outlet obstruction in men unable to undergo transurethral resection of the prostate (TURP), assessing symptoms, complications and duration of stent life.

PATIENTS AND METHODS

The Memokath stent is a coil of a nickel-titanium alloy which has 'shape memory', the lower end expanding when heated to 55 degrees C. Risks associated with inserting the stent with a flexible cystoscope under local anaesthesia are minimal. Men were selected who were either permanently or temporarily unfit for TURP. Indications included severe respiratory and cardiovascular disease. Exclusion criteria included bladder carcinoma, calculi or detrusor failure; in all, 211 men were fitted with 217 intraprostatic stents over 8 years.

RESULTS

There were 1511 TURPs during the study period; the mean age of men receiving a stent was 80.2 years, compared with 70.2 years for those undergoing TURP. The International Prostate Symptom Score decreased from a mean of 20.3 to 8.2 (P < 0.001) in the first 3 months after stent placement; there was virtually no change over 7 years. During the follow-up, 38% of men died with their stents in situ, 34% remain alive, 23% have had their stents removed for failure and 4% were removed as they were no longer required. There was a 13% migration rate and 16% repositioning rate. There were few side-effects (pain 3%, haematuria 3%, incontinence 6% and infection 6%). These frail men were more likely to die than have their stent fail.

CONCLUSION

The Memokath intraprostatic stent is a valuable addition to the armamentarium of the urologist treating elderly or frail men with advanced bladder outlet obstruction and complements existing technologies.

摘要

目的

评估热膨胀性前列腺内支架(Memokath,工程师与医生联合公司,丹麦哥本哈根)在无法接受经尿道前列腺切除术(TURP)的男性膀胱出口梗阻患者中的应用,评估症状、并发症及支架使用寿命。

患者与方法

Memokath支架是一种具有“形状记忆”功能的镍钛合金线圈,其下端在加热至55摄氏度时会膨胀。在局部麻醉下通过柔性膀胱镜插入支架的相关风险极小。入选的男性患者为永久或暂时不适合进行TURP的患者。适应症包括严重的呼吸和心血管疾病。排除标准包括膀胱癌、结石或逼尿肌功能衰竭;在8年期间,共有211名男性植入了217个前列腺内支架。

结果

研究期间共进行了1511例TURP;接受支架植入的男性平均年龄为80.2岁,而接受TURP的男性平均年龄为70.2岁。支架置入后的前3个月,国际前列腺症状评分从平均20.3降至8.2(P<0.001);7年内几乎没有变化。随访期间,38%的男性在支架在位时死亡,34%仍存活,23%因支架失效而取出,4%因不再需要而取出。迁移率为13%,重新定位率为16%。副作用较少(疼痛3%、血尿3%、尿失禁6%、感染6%)。这些身体虚弱的男性死亡的可能性大于支架失效的可能性。

结论

Memokath前列腺内支架是泌尿外科医生治疗患有晚期膀胱出口梗阻的老年或体弱男性的有效工具,是现有技术的有益补充。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验